Defining the clinical role of pharmacogenetics in antiepileptic drug therapy.
Defining the clinical role of pharmacogenetics in antiepileptic drug therapy.
复制标题
定义药物遗传学在抗癫痫药物治疗中的临床作用。
DOI：
10.1038/sj.tpj.6500379
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Ferraro,TN
中科院分区：
文献类型：
--
作者：
Dlugos,DJ;Buono,RJ;Ferraro,TN
不断积累的证据表明，遗传变异至少部分地导致了对几乎所有类别药物（包括用于治疗癫痫患者的药物）的临床反应的个体间差异。尽管最近的重点放在药物遗传学的概念，它一直很难准确地评估抗癫痫药物（AED）治疗的基因变异的相对重要性。迄今为止，AED药物遗传学研究的主要焦点一直是具有临床价值的老药，特别是苯妥英（PHT）和卡马西平（CBZ）。其他标准药物如丙戊酸（VPA）、乙琥胺（ETX）、巴比妥类药物和苯二氮卓类药物尚未进行系统研究，也没有对较新的药物如加巴喷丁、拉莫三嗪（LTG）、非氨酯、噻加宾、托吡酯（TPM）、氨己烯酸（VGB）、奥卡西平（OXC）、左乙拉西坦和唑尼沙胺进行系统研究。基础数据的这种局限性阻碍了遗传信息在目前AED临床应用中的广泛应用。
Evidence continues to accumulate suggesting that genetic variation is at least partly responsible for interindividual differences in clinical response to essentially all classes of drugs, including those used to treat patients with epilepsy. Despite the recent emphasis placed upon the concept of pharmacogenetics, it has been difficult to assess accurately the relative importance of gene variation in antiepileptic drug (AED) therapy. To date, the main focus of AED pharmacogenetic research has been older drugs of established clinical value, particularly, phenytoin (PHT) and carbamazepine (CBZ). Other standard agents such as valproic acid (VPA), ethosuximide (ETX), barbiturates and benzodiazepines have not been systematically studied, nor have newer drugs such as gabapentin, lamotrigine (LTG), felbamate, tiagabine, topiramate (TPM), vigabatrin (VGB), oxcarbazepine (OXC), levetiracetam and zonisamide. This limitation in fundamental data prohibits broad application of genetic information in the clinical use of AEDs at the present time.